全球临床化学和免疫检测产业，2023-2028

Clinical Chemistry and Immunoassay Industry, Global, 2023-2028

出版日期: 2024年10月30日 | 出版商:

Frost & Sullivan | 英文 69 Pages | 商品交期: 最快1-2个工作天内

价格

简介目录

整合、可扩展的核心实验室解决方案可推动转型成长

该分析考察了全球临床化学和免疫检测领域，该领域在体外诊断 (IVD) 市场中占据最大份额。这种基于实验室的测试使用整合/独立分析仪和各种分析/面板来支援人类健康诊断和治疗，以及支援人类健康诊断和治疗的其他解决方案和服务。

临床化学设备和测试针对体液中的各种化学物质来评估患者的健康状况和临床管理，而免疫检测设备和测试则利用抗体与抗原的结合来评估患者的健康状况和临床管理。并识别和测量特定物质。这项竞争性分析考察了提供广泛的临床化学和免疫检测系统（包括设备和耗材）的 IVD 公司。典型的最终用户包括医院、诊所、诊断实验室和研究机构。市场收益估计和预测按癌症/肿瘤、心臟病、糖尿病、感染疾病和其他应用进行分类。根据趋势，我们确定了四个成长机会，可以最大限度地发挥经济潜力并维持价值。

This analysis examines the global clinical chemistry and immunoassay sector, accounting for the highest share in the in vitro diagnostics (IVD) market. This type of lab-based testing analyzes body fluids (usually blood, urine, or saliva) using integrated/standalone analyzers and a wide range of assays/panels, among other solutions and services to support the diagnosis and treatment of human health.

While clinical chemistry instruments and tests target different chemicals in body fluids to evaluate health and the clinical management of patients, immunoassay instruments and tests measure the presence or concentration of analytes in biological liquid by using the binding of antibodies to antigens to identify and measure certain substances. This competitive analysis examines IVD companies that provide a broad menu of clinical chemistry and immunoassay systems, including instruments and consumables. Key end-user verticals comprise hospitals, clinics, diagnostic laboratories, and research institutions. The sector is segmented by applications, including cancer/oncology, cardiac, diabetes, infectious, and others, for market revenue estimations and forecasts. The study also identifies four growth opportunities that build on trends, maximize the economic potential, and sustain value.

Scope and Segmentation

Scope of Analysis
Segmentation

Growth Environment: Transformation in the Clinical Chemistry and Immunoassay Sector

Why Is It Increasingly Difficult to Grow?
The Strategic Imperative 8™
The Impact of the Top 3 Strategic Imperatives on the Clinical Chemistry and Immunoassay Industry